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Abstract 
The primary objective of this study was to examine the effects of obstructive sleep apnea 
(OSA) on resting hemodynamic variables pre- and post-cardiac rehabilitation 
(CR). Subjects were screened for OSA using an at-home screening device. Subjects were 
then divided into two design groups: subjects with likely OSA (OSA) and subjects 
without OSA (non-OSA). All patients had resting hemodynamic measurements recorded 
and performed a 6-minute walk test. Resting hemodynamics and 6-minute walk test were 
performed pre- and post-CR. The study was conducted at Rockingham Memorial 
Hospital in Harrisonburg, VA and Carilion Roanoke Community Hospital in Roanoke, 
VA where subjects completed standard early-outpatient (Phase II) Cardiac Rehabilitation. 
The sample consisted of 33 OSA subjects (age: 65.0 ± 12.4 years; AHI: 17.2 ± 12.3) and 
12 non-OSA subjects (age: 63.7 ± 11.2 years; AHI: 1.8 ±1.3). Both the OSA and the non-
OSA group had a significant improvement in BMI (p= 0.046) from baseline 
measurements to follow-up without a significant difference between groups. Both groups 
significantly improved 6-minute walk test performance (p<0.0001) from baseline to 
follow-up, with the OSA group having significantly higher values at both time points. 
The OSA group had significantly lower cardiac index values (p=0.018), ejection fraction 
values (p=0.039), and contractility index values (p=0.008) when compared to the non 
OSA group at baseline and follow-up. The OSA group had significantly higher systemic 
vascular resistance index values (p=0.027) when compared to the non-OSA group at 
baseline and follow-up. There was no significant effect for time or group by time with 
respect to any other variable. CR can facilitate in BMI improvement, while potentially 
improving 
 vi 
cardiovascular fitness in patients.  CR did not improve resting hemodynamic variables, 
regardless of OSA presence.  However, subjects with OSA appear to have diminished 
cardiac function when compared to non-OSA subjects, manifesting through increased 
systemic vascular resistance index and decreased contractility index, cardiac index, and 
ejection fraction.
Chapter One 
 
Introduction 
 
Obstructive sleep apnea (OSA) is a sleep disorder that affects roughly 3% to 7 % 
of men and 2% to 5 % of women in the general population; however prevalence is 
reported to be higher among overweight and obese populations [1]. It is estimated that 1 
in every 5 adults have at least mild OSA and 1 in every 15 adults have at least moderate 
OSA when body mass index (BMI) measurements range between 25 and 28 kg/m2 [2]. 
OSA is characterized by recurring episodes of complete or near complete collapse of the 
upper-airway during sleep [2]. An apneic event is a complete obstruction of the upper-
airway that causes a pause in respiration for a duration of ≥10 seconds. Apnea is 
associated with continued ventilatory effort and, when terminated, is followed by an 
arousal from sleep [2]. A hypopnea is a partial airway obstruction that results in a <50% 
reduction in airflow, is associated with a reduction in oxyhemoglobin saturation, and is 
often followed by sleep arousal [3]. Disease severity is measured on an apnea-hypopnea 
index (AHI), which measures the frequency of apneas and hypopneas per hour of sleep 
[3]. 
The prevalence and progression of OSA severity in the general population has 
been shown to have a strong positive association with age and BMI, with male sex, 
weight, neck size, and visceral adiposity being additional risk factors [3–7]. The presence 
of OSA, alone, can be detrimental to an individual’s health; but more serious health 
implications may occur if the disease works congruently with other cardiovascular 
disease (CVD) manifestations. When adjusted for known OSA risk factors, 
epidemiological evidence suggests a causal relationship between the presence of OSA 
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and CVD development [8]. Not only is OSA present in roughly 50% of patients with 
hypertension, but it has also been identified as an independent risk factor for developing 
hypertension [8–10].  It is estimated that in patients with coronary artery disease, roughly 
30% have OSA [8]. Furthermore, patients who experience a nocturnal myocardial 
infarction (MI) have a high likelihood of having OSA, suggesting that the presence of 
OSA may be a trigger for a MI [11]. Investigative studies on patients who experience a 
MI report that the prevalence of OSA ranges anywhere from 65.7% to 91% [11–13]. In 
heart failure patients the prevalence of OSA ranges from 12% to 53% [8].  
The severity of OSA has a strong association with CVD risk and all cause 
mortality [14–18]. This risk of CVD is mediated through the chronic exposure to 
intermittent vascular and hemodynamic fluctuations that occur during nocturnal apneic 
events. The majority of OSA patients have smaller anatomical airways, either due to a 
large neck circumference [19] or obesity [3]. Both factors contribute to the collapsibility 
of the upper-airway during sleep. The upper airway is regulated by dilator muscles that 
reflexively respond to changes in intrathoracic pressure. Reductions in airway size result 
in an increase in airway resistance and an increase in intrathoracic negative pressure 
during inspiration [3, 20]. In the awakened state, dilator muscle activation compensates 
for the airway resistance; however, dilatory muscle activation is significantly attenuated 
during sleep. In normal subjects, this results in a small degree of airflow resistance. In 
subjects with OSA, the reduction of reflex driven dilator activity leads to intermittent 
complete or near-complete collapse of the upper airway [3, 20].  
Peripheral chemoreceptors, located in the carotid bodies, primarily respond to 
fluctuations in blood oxygen retention. During apneas, oxyhemoglobin desaturation 
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stimulates peripheral chemoreceptor activity to increase sympathetic discharge, which 
progressively increases with desaturation [2, 21, 22]. The increase in sympathetic nerve 
activity is accompanied by a rise in plasma norepinephrine levels (NE), peripheral 
vasoconstriction, mean arterial pressure, heart rate, and blood pressure [21–23].  
Continued ventilatory efforts to inspire against the narrowed or collapsed airway 
results in increased intrathoracic negative pressure and hemodynamic alterations [24]. 
The cessation of breathing and the increase in intrathoracic negative pressure decreases 
venous return, impairs left ventricular (LV) relaxation, and hinders LV filling [21, 25]. 
The increase in intrathoracic negative pressure is also associated with an increase LV 
transmural pressure and causes an increase in LV afterload [26]. The increase in 
peripheral resistance contributes to the increase in LV afterload, resulting in the heart 
having to work against a greater pressure with each beat [22, 26]. The combination of 
decreased cardiac preload and increased cardiac afterload results in a decrease in stroke 
volume and cardiac output during apnea [25]. The peripheral vasoconstriction helps, in 
part, to maintain blood pressure and venous return during the obstruction [21]; however, 
compared to baseline values, there is an overall decrease in cardiac output and cardiac 
index; cardiac index being cardiac output in relation to body surface area [27]. The acute 
physiological fluctuations that occur during apneas are analogous to hypopneas [2].   
Apneas and hypopneas are terminated by central nervous system arousals that 
activate the upper airway dilator muscles [25]. The resumption of breathing results in a 
withdrawal of sympathetic discharge, an increase in venous return, temporary tachycardia, 
and a significant increase in cardiac output and cardiac index [21, 27]. The increase in 
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cardiac output and the surge of blood flow against vasoconstricted arteries causes 
transient spikes in blood pressure that can reach levels as high as 240/130 mmHg [21].  
If left untreated, the apneic episodes associated with OSA can lead to vascular and 
cardiac alterations. The presence of OSA appears to be predominately responsible for 
endothelial dysfunction [28]. Patients with OSA have increased nighttime and daytime 
sympathetic nerve activity when compared to normal controls, [21, 23], which is 
associated with an increase in plasma NE levels [23]. The increase in sympathetic activity 
and NE is associated with an increase in vasoconstriction [29]. Furthermore, circulating 
levels of nitric oxide (NO), a potent vasodilator, are suppressed in patients with OSA [30, 
31]. Chronic exposure of increased pressure on the endothelium could lead to a decrease 
in NO biosynthesis and, therefore, endothelial dysfunction [31]. OSA can activate 
inflammatory pathways that can lead to an increase in oxidative stress and a chronic 
systemic low-grade inflammatory state in patients, regardless of body fat percentage [28, 
32, 33]. Chronic exposure to oxidative stress and inflammation can lead to endothelial 
damage. Finally, patients with OSA have been shown to have higher circulating levels of 
prothrombotic biomarkers [34]. Circulating levels of plasminogen activator inhibitor 
type-1 and fibrinogen have been recorded in patients with OSA and have a positive 
association with AHI [34]. These biomarkers are further indicators of endothelial 
dysfunction and create a chronic prothrombotic state. Endothelial dysfunction increases 
the risk of hypertension, atherosclerotic lesion development, cardiac ischemia, coronary 
artery damage, MI, heart failure, or sudden death [3, 32, 35, 36].  
Repetitive surges in blood pressure upon the cessation of apnea may lead to 
sustained systemic hypertension and contribute to cardiac adaptations [8, 14, 16]. Clinical 
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implications of chronic exposure to intrathoracic pressure changes and large spikes in 
blood pressure are cardiac remodeling and ventricular dysfunction.  Independent of other 
disease manifestations, OSA can impair LV relaxation, which may be a consequence of 
the intermittent cardiac overload during apneic events [37]. Other cardiac abnormalities 
are observed as OSA severity progresses. Severe OSA is associated with increased 
incidence of LV hypertrophy. This may be due to the increased transmural pressure, 
hypoxemia, and increased sympathetic nervous system activity that occur during 
nocturnal obstructive apneas. LV hypertrophy may also manifest from the high afterload 
that is associated with sustained hypertension, which is also common amongst OSA 
patients [38]. Other cardiac manifestations associated with increasing disease severity are 
left atrial enlargement, right atrial enlargement, and right ventricular hypertrophy; 
however, even in the presence of these structural abnormalities, ejection fraction appears 
to be maintained [38, 39]. Nonetheless, these structural adaptations do influence the risk 
for cardiac arrhythmias [40, 41], the risk of congestive heart failure [39], and the risk of 
sudden death [42]. It is the combination of these physiological alterations that make OSA 
an important risk factor for CVD morbidity. 
Recent data suggests that about 53% of patients entering a cardiac rehabilitation 
(CR) program are at high risk for having OSA and, of that 53%, 43% of those patients 
may be undiagnosed and untreated [43]. Reasons for entering a CR program could range 
from MI, coronary artery bypass graph surgery, percutaneous coronary intervention, 
cardiac transplant, chronic heart failure, or cardiac valve repair or replacement [44]. CR 
programs significantly reduce the risk of a secondary fatal MI, mortality from coronary 
artery disease, and overall mortality through exercise-related health gains [45, 46]. 
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Exercise training provided by a CR program is beneficial for decreasing blood 
coagulability, the ability to form clots, as well as increasing fibrinolysis, the mechanism 
that breaks down clot formation; these adaptations thereby decrease the overall risk of 
thrombosis [44].  Exercise training improves the inflammatory state of patients by 
decreasing inflammatory markers such as C-Reactive protein [47]. Ultimately, the 
reduction in inflammation can improve endothelial function, in addition to exercise 
related gains in endothelium- dependent vasodilation [44]. Additional benefits of exercise 
training include attenuated hyperactivity of the sympathetic nervous system, improved 
exercise and functional capacity levels, improved lipid profiles, moderate reduction in 
weight and adiposity, improved submaximal heart rate levels, and improved systolic 
blood pressures [44–46]. These benefits reduce the risk of a secondary coronary event 
and overall mortality.     
Patients entering a CR program may perform a symptom limited exercise capacity 
test to evaluate current fitness levels. Patients with OSA show altered cardiopulmonary 
response during exercise testing, which could indicate disease specific alterations to 
exercise capacity. When compared to normal controls, middle-aged OSA patients show 
elevated systolic and diastolic blood pressures during exercise testing [48–50] and an 
attenuated decline in systolic blood pressure during active recovery [48]. This may be a 
result of increased peripheral resistance [50], although this finding has not been 
confirmed in younger subjects with OSA [51]. Attenuated HR recovery has been 
observed in OSA patients post exercise [51–53], which is an independent predictor of all-
cause mortality [54]. 
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 In normotensive OSA subjects with normal resting LV function, OSA subjects 
had lower cardiac output and stroke volume responses to exercise when compared to 
control patients [55]. However, this response to exercise was improved after 3 months of 
continuous positive airway pressure therapy, suggesting that there is a relationship 
between the presence of OSA and LV impairment during exercise [55]. Finally, patients 
with OSA have been shown to have significantly lower lactate levels at maximal exercise 
and a slower lactate removal rate during recovery when compared to control patients. The 
lower levels of maximal blood lactate may suggest impaired glycolytic metabolism 
during exercise and the delayed lactate removal rate may suggest impaired oxidative 
metabolism post exercise [50].  
Patients with OSA can safely participate in prolonged exercise training programs 
and experience a decrease in disease severity. OSA patients regularly participating in 
exercise training have reported significant improvements in subjective feelings of fatigue, 
tension, physical functioning, and overall health perception [56]. With exercise training, 
significant improvements have been reported in sleep efficiency, sleep onset latency, and 
reduced OSA severity, regardless of reductions in body weight [57, 58]. The goal of these 
interventions was to observe the effects of exercise on disease severity; however, the 
effects of exercise training on hemodynamic adaptations in patients with OSA were not 
measured.   
The literature is mixed in regards to resting hemodynamic variables between 
patients with OSA and patients without. In the absence of CVD, subjects with OSA have 
been reported to have LV systolic and diastolic dysfunction, shown through lowered LV 
ejection fractions, reduced LV peak emptying rate, and reduced LV peak filling rate [59, 
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60]. However, normal ejection fraction values have been reported in subjects with severe 
OSA [38]. Some report significantly higher resting heart rate values in patients with OSA 
when compared to control patients [53], although no difference between groups has also 
been reported [23]. There appears to be no difference in stroke volume index and cardiac 
index between OSA and control patients [48]. Some studies report an increase in resting 
systolic blood pressure in patients with OSA [48] and some report no difference [55].   
Exercise programs for patients in CR are beneficial for increasing exercise 
capacity and improving hemodynamic variables. In patients diagnosed with OSA, in the 
absence of existing CVD morbidities, the literature is mixed regarding resting 
hemodynamic variables. Resting hemodynamics may be exaggerated between patients 
with OSA and without OSA in a CR program, where other comorbidities are present. 
Both patients with OSA and patients without OSA can see cardiopulmonary benefits 
from a structured exercise program.  However, pressure and volume fluctuations that 
occur during apneas may attenuate the hemodynamic improvements a patient with 
untreated OSA may experience from a CR program when compared to patients without 
OSA.  
Purpose 
 The purpose of this study is to examine the effects of untreated OSA on resting 
hemodynamic variables pre- and post-CR. It is hypothesized that subjects with 
undiagnosed and untreated OSA will see attenuated hemodynamic improvements 
following CR when compared to subjects without OSA. 
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Assumptions 
 For the duration of the study, it is assumed that subjects will consistently and 
routinely take part in the CR program and that the conditions outside the scope of the 
study will remain consistent.   
Delimitations 
 Subjects will be limited to CR patients at Rockingham Memorial Hospital and 
Carilion Roanoke Community Hospital. Subjects will be screened for OSA with an at 
home screening device.   
Limitations  
Subjects will have 1 week upon CR entry to decide if they want to participate in 
the study. In addition, subjects will not be excluded based on current medication use.  
Definition of Terms 
Mild OSA: AHI of 5-15[2, 7] 
Moderate OSA: AHI of 15-30 [2, 7] 
Severe OSA: AHI of 30 or greater [2, 7] 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter II 
 
Methodology 
 
 The purpose of this study was to examine the relationship between the 
presence of OSA in patients with cardiovascular disease on resting hemodynamic 
variables in a cardiac rehabilitation (CR) setting.  This study has received the 
International Review Board approval at James Madison University, at Rockingham 
Memorial Hospital, and at Carilion Roanoke Community Hospital.   
Subjects 
 
Subjects consisted of patients recently admitted into the Rockingham Memorial 
Hospital and the Carilion Roanoke Community Hospital Cardiac Rehabilitation programs. 
All subjects were informed of the study during the CR orientation visit by either the 
clinical exercise physiologist or the nursing staff. If interested in the study, subjects were 
sent home with Informed Consent documentation and an Epworth Sleepiness Scale (ESS). 
All subjects were patient volunteers. The study consisted of 45 subjects, 32 males and 13 
females. Age of the subjects ranged from 30 to 84 years, with a mean (±SD) age of 
45±12 years. Subject characteristics are described in detail in Table 1. The study had two 
exclusion criteria: subjects who had diagnosed pulmonary disease and/or subjects who 
were currently being treated for OSA were excluded from the study. There were no other 
exclusion criteria on the basis of age, gender, or health history. 
Procedures 
Baseline Assessment  
On the first day of CR, subjects returned with their completed Informed Consent 
and ESS. The ESS conist of eight situations that are likely to evoke daytime sleepiness 
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for the respondent. Responders are asked to rank the likelihood of dozing off during the 
eight situations on a scale from 0-3, with 0 indicating “never dozes” and 3 indicating a 
“high chance of dozing.” The scores are then added together to give a score between 0 
and 24, which corresponds to low levels of daytime sleepiness and high levels of daytime 
sleepiness, respectively. The ESS has been shown to distinguish normal patients from 
patients with various sleep related disorders, such as OSA, narcolepsy, and idiopathic 
hyperinsonmia [61]. In patients with OSA, a significant correlation has been reported 
between ESS scores, respiratory disturbance index, and minimium oxyhemoglobin 
saturation levels, confirmed through overnight polysomnography [61].  
Subject height was measured with a stadiometer and weight was measured with 
an electronic scale. Body mass index (BMI) was calculated by converting weight into 
kilograms and height into meters, then using the equation: BMI = weight (kg) / height (m) 
2. Resting blood pressure was measured manually using a sphygmomanometer and a 
stethoscope while the subject was in supine position.  
 Sex, age, weight, height and resting blood pressure were manually entered into 
the PhysioFlow software and resting PhysioFlow measurements were recorded for 10 
minutes while subjects were in the supine position. The PhysioFlow (PhysioFlow PF-05 
Lab1, NeuMeDx, Bristol, PA) is non-invasive, impedance cardiograph that measures 
various hemodynamic parameters. The PhysioFlow measures heart rate, stroke volume, 
cardiac output, cardiac index, contractility index, systolic arterial pressure, diastolic 
arterial pressure, ejection fraction, left ventricular ejection time, end diastolic volume, 
systemic vascular resistance, and systemic vascular resistance index. The device consists 
of 6 PhysioFlow Skintact pre-gelled Ag/AgCl electrodes, a 6-lead ECG cable connector, 
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and is compatible with Microsoft Windows 2000 XP or a later operating system. Subjects 
need to be prepped with alcohol pads and attached with the 6 pre-gelled electrodes. 
Initiation of a 30-beat calibration cycle begins continuous hemodynamic data collection. 
The electrodes, placed on the neck and chest, detect electrical and impedance changes in 
the thorax, which are used to measure and calculate the hemodynamic parameters. The 
PhysioFlow has been validated to provide clinically acceptable, non-invasive evaluation 
of cardiac performance [62].     
All subjects performed a 6-minute walk test after resting PhysioFlow 
measurements were recorded. The distance each subject walked in 6 minutes was 
measured in feet. Heart rate and rating of perceived exertion were recorded every minute 
of the test. Following the 6-minute walk test, subjects sat in a chair for a 5-minute 
recovery period while heart rate and blood pressure were measured every minute of 
recovery. The 6-minute walk test is a reliable and valid measure of cardiovascular 
endurance in the elderly [63].   
After the 5-minute recovery, subjects were given an at-home apnea screening 
device (ApneaLink Plus, ResMed Corp., San Diego, CA) to screen for possible OSA. The 
device consists of an adjustable Velcro belt that holds in place a respiratory effort sensor, 
a nasal cannula, and a pulse oximeter. The ApneaLink Plus measures respiratory nasal 
airflow, snoring, blood oxygen saturation, heart rate, and respiratory effort during sleep. 
The Apnealink Plus records partial or complete respiratory obstructions, duration of 
obstructions, lowest and highest heart rate measurements, lowest and highest blood 
oxygen saturation measurements, and the time points that these events occur during sleep. 
The ApneaLink Plus provides a reliable initial assessment of suspected OSA [64]. A copy 
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of instructions on how to use the ApneaLink Plus was sent home with the subject.  In 
addition, an accelerometer (ActiGraph GT3X+, ActiGraph, Pensacola, FL) was given to 
the subjects with instructions on its use.  The accelerometer is a device that detects and 
measures movement during sleep while being worn on the non-dominant wrist. The 
accelerometer records the time of sleep onset, total sleep time, total awake time, number 
of awakenings, and the average duration of awakenings.  Data was downloaded on to a 
computer and analyzed with proprietary software.  These devices have been validated 
relative to measures obtained through polysomnography [65, 66].  
ApneaLink reports were sent to a certified sleep technician to analyze the data. 
Based on the technician report, subjects were divided into either an OSA group or a non-
OSA group. Subjects were assigned to the OSA group if AHI ≥	 5. Of the 45 subjects, 33 
were classified as OSA and 12 were classified as non-OSA. All subjects then participated 
in scheduled CR sessions at their respective hospital. Subjects completed an average of 
25.6 ± 8.4 CR sessions. The average stay in CR was between 2-3 months, with the least 
being 1 month and the most being 4 months. CR staff was blinded to the group 
designation of each patient.  
Follow-up Assessment 
On the subjects’ last day of CR participation, all hemodynamic variables were re-
assessed and the 6-minute walk test was repeated.  
Statistical Analysis  
 
 The statistical analysis program used for this study was the IBM SPSS Statistics 
version 20. A mixed design ANOVA analysis was used to analyze mean values of weight, 
BMI, physioflow variables, and 6-minute walk test results from baseline to follow-up. 
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Group was the between subject factor (OSA and non-OSA) and time was the within-
subject factor (baseline and follow-up). In cases where significance was found for the 
Mauchly's test of sphericity (cardiac index, ejection fraction, contractility index, and 
systemic vascular resistance), the Greenhouse-Geisser correction factor was used to 
adjust the F-test accordingly and its significance accordingly.  All data are presented 
mean ± the standard deviation. The statistical significance for all tests was set a 
priori at p< 0.05. 
Chapter III 
 
Journal Manuscript 
 
Journal Format: Sleep and Breathing 
 
Manuscript Title: The Implications of Undiagnosed Obstructive Sleep Apnea on Resting 
Hemodynamic Variables in Cardiac Rehabilitation Patients.   
ABSTRACT  
 
Study Objective: The primary objective of this study was to examine the effects of 
obstructive sleep apnea (OSA) on resting hemodynamic variables pre- and post-cardiac 
rehabilitation (CR).  
Design: Subjects were screened for OSA using an at-home screening device. Subjects 
were then divided into two design groups: subjects with likely OSA (OSA) and subjects 
without OSA (non-OSA). All patients had resting hemodynamic measurements recorded 
and performed a 6-minute walk test. Resting hemodynamics and 6-minute walk test were 
performed pre- and post-CR.  
Setting: The study was conducted at Rockingham Memorial Hospital in Harrisonburg, 
VA and Carilion Roanoke Community Hospital in Roanoke, VA.  
Participants: 33 OSA (age: 65.0 ± 12.4 years; AHI: 17.2 ± 12.3) and 12 non-OSA (age: 
63.7 ± 11.2 years; AHI: 1.8 ±1.3).  
Intervention: Standard early-outpatient (Phase II) CR. 
 
Measurements and Results: Both the OSA and the non-OSA group had a significant 
reduction in BMI (OSA= -0.31 kg/m2; non-OSA= -0.36 kg/m2) from baseline 
measurements to follow-up without a significant difference between groups. Both groups 
significantly improved 6-minute walk test performance (OSA= +322.86 ft; non-OSA= 
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+212.87 ft), with the OSA group having significantly higher values at both time points 
(p=0.018). When compared to the non-OSA group, the OSA group had significantly 
lower values at both baseline and follow-up for cardiac index (2.1 L/min/m2 and 2.2 
L/min/m2 vs. 2.6 L/min/m2 and 2.6 L/min/m2; baseline and follow-up, OSA vs. non-OSA, 
respectively, p=0.018), ejection fraction (57.2% and 59.6% vs. 65.4% and 65.4%; 
baseline and follow-up, OSA vs. non-OSA, respectively, p=0.039), and contractility 
index (105.2 and 127.8 vs. 162.1 and 160.7; baseline and follow-up, OSA vs. non-OSA, 
respectively, p=0.008). When compared to the non-OSA group, the OSA group had 
significantly higher values at both baseline and follow-up for systemic vascular resistance 
index (3730.2 dyn·s/cm5 and 3357.2 dyn·s/cm5 vs. 2690.2 dyn·s/cm5 and 2660.8 
dyn·s/cm5; baseline and follow-up, OSA vs. non-OSA, respectively, p=0.027). There was 
no significant effect for time or group by time with respect to any other variable.  
Conclusions: CR can facilitate in BMI improvement, while potentially improving 
cardiovascular fitness in patients.  CR did not improve resting hemodynamic variables, 
regardless of OSA presence.  However, when standardizing for body surface area, 
subjects with OSA appear to have diminished cardiac function when compared to non-
OSA subjects.  
Key Words: Obstructive sleep apnea, hemodynamics, cardiac rehabilitation 
 
 
 
 
 
 
 
 
 
 
 
  
17 
INTRODUCTION 
 
Obstructive sleep apnea (OSA) is a sleep disorder that affects roughly 3% to 7 % 
of men and 2% to 5 % of women in the general population; however, prevalence is 
reported to be higher among the overweight and obese[1]. It is estimated that 1 in every 5 
adults have at least mild OSA and 1 in every 15 adults have at least moderate OSA when 
body mass index (BMI) measurements range between 25 and 28 kg/m2 [2]. OSA is 
characterized by recurring episodes of complete (apnea) or near complete (hypopnea) 
collapse of the upper-airway during sleep [2].  
Hypopneas occur when there is a partial collapse of the airway, resulting in a 
<50% reduction in airflow and is usually associated with a reduction in oxyhemoglobin 
saturation [3]. An apnea is a complete collapse of the airway followed by continued 
ventilator effort [3]. Hypopneas and apneas create a hypoxemic environment that is 
associated with an incremental increase in sympathetic nerve activity accompanied by a 
rise in plasma norepinephrine levels, peripheral vasoconstriction, mean arterial pressure, 
heart rate, and blood pressure [2, 4–6]. The continued ventilatory efforts against a 
narrowed or collapsed airway result in increased intrathoracic negative pressure and 
hemodynamic alterations [2, 7]. Apneas and hypopneas are terminated by central nervous 
system arousals [7, 8]. The resumption of breathing results in a withdrawal of 
sympathetic discharge, an increase in venous return, temporary tachycardia, and a 
significant increase in cardiac output (CO) and cardiac index (CI) [4, 9]. The increase in 
CO and the surge of blood flow against vasoconstricted arteries causes transient spikes in 
blood pressure (BP) that can reach levels as high as 240/130 mmHg [4]. OSA has been 
identified as an independent risk factor for developing hypertension [10] and coronary 
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artery disease [8], in addition to increasing the risk for myocardial infarction (MI) [3], 
congestive heart failure [11], and an increase in all cause mortality [12].  
Recent data suggests that about 53% of patients entering a cardiac rehabilitation 
(CR) program are at high risk for having OSA and, of that 53%, 43% of those patients 
may be undiagnosed and untreated [13]. CR programs significantly reduce the risk of a 
secondary fatal MI and all-cause mortality through exercise-related health gains [14, 15]. 
Exercise training provided by a CR program can benefit patients by decreasing the risk of 
thrombosis, improving inflammatory markers, improving exercise and functional 
capacity levels, improving lipid profiles, providing moderate reductions in weight and 
adiposity, improving submaximal heart rate (HR) levels, and improving systolic BP [14–
16].  
Patients with OSA can safely participate in progressive and prolonged exercise 
training programs without adverse affects and see improvements in disease severity [17–
19] . OSA patients regularly participating in exercise training have reported significant 
improvements in subjective feelings of fatigue, physical functioning [20], and reduced 
OSA severity, regardless of reductions in body weight [17]. However, the effects of 
exercise training on hemodynamic adaptations in patients with OSA have not been 
measured.   
Patients with OSA show altered cardiopulmonary responses to acute exercise 
testing, which may indicate disease specific alterations to exercise capacity. When 
compared to normal controls, middle-aged OSA patients show elevated systolic and 
diastolic BP during exercise testing [21–23] and an attenuated decline in systolic BP 
during active recovery [21], although this finding has not been confirmed in younger 
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subjects with OSA [24]. Attenuated HR recovery has been observed in OSA patients post 
exercise [24–26], which is an independent predictor of all-cause mortality [27]. 
The literature is mixed in regards to resting hemodynamic variables between 
patients with and without OSA. Subjects with OSA have been reported to have left 
ventricular (LV) systolic and diastolic dysfunction, as indicated by lowered LV ejection 
fractions (EF), reduced LV peak emptying rate, reduced LV peak filling rate [28, 29]. 
However, normal EF values have been reported in subjects with severe OSA [30]. Some 
report significantly higher resting HR values in patients with OSA when compared to 
control patients [26]; although no difference between groups has also been reported [5]. 
Current literature indicates no difference in stroke volume (SV) index and CI between 
OSA and control patients [11, 21]. Some studies report an increase in resting systolic BP 
in patients with OSA [21], while others report no difference [31]. Subjects from these 
previous studies, however, were all subjects with OSA but without evidence of CVD.   
The difference in resting hemodynamic variables may be exaggerated between 
patients with OSA and patients without OSA in a CR program, where other comorbidities 
are present. Both patients with OSA and patients without OSA can see cardiopulmonary 
benefits from a structured exercise program. The adverse health implications of the 
presence of OSA may attenuate the cardiovascular and hemodynamic improvements a 
patient with untreated OSA may experience from a CR program when compared to 
patients without OSA.  
The purpose of this study is to examine the relationship between OSA and CR 
outcomes on resting hemodynamic variables in patients with cardiovascular disease.  It is 
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hypothesized that patients with undiagnosed OSA will see attenuated cardiovascular and 
hemodynamic improvements following CR compared to their non-OSA counterparts. 
MATERIALS AND METHODS 
 
Subjects 
 
Subjects consisted of patients recently admitted into the Rockingham Memorial 
Hospital and the Carilion Roanoke Community Hospital Cardiac Rehabilitation programs. 
All patients were informed of the study during the CR orientation visit by CR staff. If 
interested in the study, patients were sent home with Informed Consent documentation 
and an Epworth Sleepiness Scale (ESS). All subjects were patient volunteers. The study 
consisted of 45 subjects (32 males and 13 females). Subjects ranged in age from 30 to 84 
years, with the mean age being 45 (SD ±12). Subject characteristics are described in 
detail in Table 1. The study had two exclusion criteria: subjects who had diagnosed 
pulmonary disease and/or subjects who were currently being treated for OSA were 
excluded from the study. There were no exclusion criteria on the basis of age, sex, or 
health history.  All methods and procedures, approved by the Institutional Review Boards 
of James Madison University, Radford University, Rockingham Memorial Hospital and 
Carilion Roanoke Community Hospital, were explained to the subjects, who then signed 
a written informed consent form.   
Baseline Assessment 
 
On the first day of CR, subjects returned with their completed Informed Consent 
and the ESS. The ESS has been shown to distinguish normal patients from patients with 
various sleep related disorders, such as OSA, narcolepsy, and idiopathic hyperinsonmia 
[32]. In patients with OSA, a significant correlation has been reported between ESS 
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scores, respiratory disturbance index, and minimium oxyhemoglobin saturation levels, 
confirmed through overnight polysomnography [32].  
Subject height was measured with a stadiometer and weight was measured with 
an electronic scale. BMI was calculated from measured weight and height (kg /m 2). 
Resting BP was measured manually using a sphygmomanometer and a stethoscope after 
the subject had been in the supine position for a minimum of 5-minutes.   
Hemodynamic Measurement 
 Resting PhysioFlow measurements were recorded for 10 minutes while subjects 
were in the supine position. The PhysioFlow (PhysioFlow PF-05 Lab1, NeuMeDx, 
Bristol, PA) is non-invasive, impedance cardiograph that measures and calculates various 
hemodynamic parameters. These parameters are measured from electrodes placed on the 
neck and chest that detect electrical and impedance changes in the thorax. The 
PhysioFlow measures HR, SV, CO, CI, systolic arterial pressure, diastolic arterial 
pressure, contractility index (CTi), EF, LV ejection time, end diastolic volume, systemic 
vascular resistance, and systemic vascular resistance index (SVRi) [33].  
6-Minute Walk Test 
All subjects performed a 6-minute walk test after resting PhysioFlow 
measurements [34]. The distance each subject walked in the 6 minutes was measured in 
feet. HR and rating of perceived exertion were recorded every minute of the test. 
Following the 6-minute walk test, subjects sat in a chair for a 5-minute recovery period. 
HR and BP were measured every minute of recovery.  
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Home Sleep Evaluation 
Subjects were then given an at-home apnea screening device (ApneaLink Plus, 
ResMed Corp., San Diego, CA) to screen for possible OSA. The ApneaLink Plus 
measures respiratory nasal airflow, snoring, blood oxygen saturation, heart rate, and 
respiratory effort during sleep. The ApneaLink Plus records partial or complete 
respiratory obstructions, duration of obstructions, lowest and highest heart rate 
measurements, lowest and highest blood oxygen saturation measurements, and it will 
record the time points that these events occur during sleep [35]. A copy of instructions on 
how to use the ApneaLink Plus was sent home with the patient.    
ApneaLink reports were sent to a certified sleep technician to analyze the data. 
Based on technician report, subjects were divided into either an OSA group or a non-
OSA group. Subjects were classified as having OSA if AHI ≥5. Of the 45 subjects, 33 
were classified as likely having OSA and 12 were classified as non-OSA. All subjects 
then participated in scheduled CR sessions at their respective hospital. Subjects 
completed an average of 25.6 ± 8.4 CR sessions. The average stay in CR was between 2-
3 months, with the least being 1 month and the most being 4 months. CR staff was 
blinded to the severity of OSA in each subject.  
Follow-up Assessment 
 
On the subjects’ last day of CR participation, all hemodynamic variables were re-
assessed and the 6-minute walk test was repeated.  
Statistical Analysis 
 
 The statistical analysis program used for this study was the IBM SPSS Statistics 
version 20. A mixed design ANOVA analysis was used to analyze mean values of weight, 
  
23 
BMI, physioflow variables, and 6-minute walk test results from baseline to follow-up. 
Group was the between subject factor (OSA and non-OSA) and time was the within-
subject factor (baseline and follow-up). In cases where significance was found for the 
Mauchly's test of sphericity (cardiac index, ejection fraction, contractility index, and 
systemic vascular resistance), the Greenhouse-Geisser correction factor was used to 
adjust the F-test accordingly and its significance accordingly.  All data are presented 
mean ± the standard deviation. The statistical significance for all tests was set a 
priori at p< 0.05.  
RESULTS 
Subject Characteristics 
 
 Baseline characteristics for each group are presented in Table 1. From baseline to 
follow-up, both groups had a significant reduction in BMI regardless of the presence of 
OSA (p=0.046). Both groups had a significant main effect for time in 6-minute walk test 
performance from baseline to follow-up (p=0.000).  A significant main effect for group 
was also observed, as the OSA group had significantly higher values across both time 
points (p=0.018). There was no significant effect for time or group by time with respect 
to age, HR, systolic arterial pressure, or diastolic arterial pressure.  
PhysioFlow Measurements 
  
PhysioFlow measurements before and after CR participation for each group are 
presented in Table 2. There was no significant effect for time or group by time with 
respect to SV, CO, LV ejection time, end diastolic volume, and systemic vascular 
resistance. There was a significant main effect for group observed in several resting 
variables. The OSA group had significantly lower CI (p=0.018), EF (p=0.039), and CTi 
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(p=0.008) and a significantly higher SVRi when compared to the non OSA group at both 
time points (p=0.027).  
DISCUSSION 
 
The main finding of this study is that, in either group, hemodynamic variables did 
not significantly change from the beginning to the end of CR. This finding contradicts 
our hypothesis that subjects with untreated OSA would have diminished hemodynamic 
improvements at the completion of CR when compared to their non-OSA counterparts. 
Although the CR intervention did not improve resting hemodynamic variables, there are 
some novel findings of this study. CI, EF, and CTi values were significantly lower and 
SVRi values were significantly higher in the OSA group regardless of the CR 
intervention, which may indicate that the resting cardiac physiology differs between the 
two groups. The index values standardize these variables by removing the effect of 
varying body surface areas among subjects; for example, CI is equal to cardiac output 
relative to body surface area. The findings of this study suggest that the presence of 
untreated OSA may manifest disease specific cardiovascular alterations and may impact 
overall cardiac performance.  
CTi represents the maximal velocity of ejected blood flow and is a good surrogate 
for contractility. CTi can be derived from pressure-volume relationships that depict the 
effectiveness of the heart to pump against the peripheral resistance. Specific variables of 
interest for CTi include EF and afterload stress [36]. In the present study, the decrease in 
EF coupled with the increase in SVRi may contribute to the overall decrease in the 
contractile state, CTi, of the myocardium. These alterations might be a reflection of an 
increased demand on the heart to overcome a greater peripheral resistance with each 
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cardiac cycle. The decrease in CTi observed in the subjects with OSA may be a result of 
chronic exposure to pressure and volume changes that occur at the end of apneic events. 
When apneas are terminated, the withdrawal of sympathetic discharge results in a rapid 
increase in venous return and a significant increase in CO [4, 9]. CO increases before 
peripheral vasodilation occurs, resulting in large increases in BP [4]. Over time, these 
pressure changes could lead to cardiac remodeling. Martinka et al observed how cardiac 
structure is affected by high blood pressure variability in normotensive rats. Twelve 
weeks of exposure to large surges in BP evoked cardiac hypertrophy and decreased LV 
contractility index [37]. The pressure overload promoted collagen synthesis and 
deposition into the myocardium of the rats, contributing to cardiac hypertrophy and 
increased LV stiffness. The authors further speculated that the decrease in LV 
contractility was a result of decreased calcium transit [37]. Patients with untreated OSA 
have been shown to have an increased incidence of left atrial enlargement, right atrial 
enlargement, LV hypertrophy, and RV hypertrophy [11, 30, 38]. Given that the study 
subjects were middle-aged, mean age 65±12 years, it is possible that they have had 
significant OSA for some time prior to it being identified.  This would result in prolonged 
exposure to intermittent pressure and volume changes during apneic events that could 
lead to structural remodeling of the myocardium and the decrease in the CTi observed.  
Subjects in the OSA group had lowered CI when compared to the non-OSA group. 
This contradicts the findings of Kaleth et al [21]and Romero-Corral et al [11], who found 
no difference in CI between OSA and control subjects. Kaleth et al observed the 
cardiopulmonary response to exercise testing in healthy, inactive OSA subjects, mean age 
45.6±10.7 years, compared to similarly matched controls. Prior to exercise testing, 
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subjects with OSA did not have significantly different resting CI when compared to the 
control subjects [21]. Romero-Corral et al studied right and left ventricular performance 
in middle-aged subjects with mild, moderate, and severe OSA. Subjects with coronary 
artery disease were included in the sample; however, some exclusion criteria were 
cardiac surgery, presence of a permanent pacemaker, or moderate to severe valvular 
disease. In all subjects with OSA, regardless of disease severity, CI was not significantly 
different then control subjects [11].  The subjects in the present study were, on average, 
older than the subjects of the aforementioned studies, and were recently diagnosed with 
significant CVD.  
Cardiac output is equivalent to HR multiplied by SV. Factors that influence SV 
are end diastolic volume and end systolic volume, with end systolic volume being the 
volume of blood in the ventricle at the end of contraction [39]. Although the PhysioFlow 
did not estimate this variable, components that effect end systolic volume are myocardial 
contractility and LV afterload [39]. The decrease in CTi, EF, and the increase in SVRi 
observed in the OSA group could represent an overall reduction in the volume of blood 
being pumped through the ventricles with each cardiac cycle. Ultimately, this would 
contribute to the reduction in CI observed.   
The present finding of lowered EF in subjects with OSA has not been consistently 
confirmed. Romero et al [11] observed right and left ventricular performance in 27 
control subjects, 18 subjects with mild OSA, and 40 subjects with moderate- to-severe 
OSA using Doppler echocardiography. The study reported impaired global RV 
performance, LV performance, and an increased left atrial volume index across all 
degrees of OSA severity; however, EF was preserved. The control group had an average 
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EF of 61.6±6.2 and the moderate to severe OSA group had an average EF of 62.3±6.5. 
Other studies show similar EF preservation [30, 40]; however, in all studies, subjects with 
known  CVD or ventricular dysfunction were excluded. Nahmias et al [41] observed right 
and left ventricular dysfunction in obese subjects with OSA, with dysfunction defined as 
a RV EF <40% and LV EF <50%. In the presence of RV dysfunction, subjects with OSA 
had RV EF of 31±1 and LV EF of 55±2 when compared to subjects without OSA, 44±2 
and 65±2 respectively. Similar results were seen in the present study where, at both time 
points, subjects with OSA had significantly lowered EF when compared to subjects 
without OSA. Although the values in this study and prior studies were within normal EF 
range and do not signify a clinically depressed EF, subjects with OSA appear to have 
lower EF when compared to their non-OSA counterparts.  
An increased SVRi was observed in the OSA group when compared to the non-
OSA group even in the absence of BP differences. Several mechanisms associated with 
untreated OSA promote an increase in vasoconstriction. Patients with OSA have 
increased nighttime and daytime sympathetic nerve activity [4, 5], increased plasma 
norepinephrine (NE) levels [5], and increase endothelin [42, 43] when compared to 
normal controls; all three of which contribute to peripheral vasoconstriction [42, 44]. 
Furthermore, circulating levels of nitric oxide (NO), a potent vasodilator, are suppressed 
in patients with OSA [45, 46].  The chronic exposure to increased pressure on the 
endothelium could lead to a decrease in NO biosynthesis, endothelial dysfunction [46], 
and hypertension. It has been reported that the renin-angiotensin-aldosterone system is 
upregulated in patients with OSA as well [42, 43, 47]. This process increases 
vasoconstriction, promotes sodium reabsorption, and raises BP. The renin secretion can 
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be stimulated through renal hypoxia or through increased sympathetic activity, which is 
chronically elevated in patients with OSA [42, 47]. Because medications were not 
controlled for in the present study, it is possible that the use of hypertension medications 
among subjects accounted for the fact that there was no observed difference in BP. 
However, the various mechanisms of OSA induced vasoconstriction may contribute to 
the increased SVRi observed, without an overall increase in BP. Mean arterial pressure, 
the flow of blood through the aorta and its arteries, is equal to CO multiplied by vascular 
resistance [48]. It is possible that the decrease in CI coupled with the increase in SVRi 
resulted in no net change in pressure. 
A secondary finding in the present study is that all subjects, regardless of the 
presence of OSA, improved BMI and improved 6-minute walk test performance by the 
end of CR.  Although statistically significant, the improvement in BMI was relatively 
small, mediated by little weight loss. Caution should also be used when interpreting the 
improved 6-minute walk test results. Although used as a tool to assess functional capacity, 
there is considerable variability in 6-minute walk test performance between repeated 
trials, possibly due to increased familiarization [49, 50]. It is recommended that subjects 
perform at least two 6-minute walk tests at baseline to get an accurate representation of 
initial exercise capacity and to track change over time [50]. For this study, subjects only 
performed one 6-minute walk test at baseline and at follow-up. Familiarization or 
improved self-efficacy could have contributed to the significant changes in test 
performance between time points. Therefore, it cannot be said with certainty that all 
subjects significantly improved fitness levels over the course of CR.  
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It is of particular interest that this study did not report any significant changes in 
resting hemodynamic variables, regardless of OSA. Subjects in the current study 
completed an average of 25.6 ± 8.4 CR sessions. This resulted in an average stay in CR 
between 2-3 months, with the least being 1 month and the most being 4 months. Previous 
findings suggest that elderly subjects can improve resting hemodynamics variables with 
moderate to vigorous aerobic training in the absence of CVD [51, 52]  and it has been 
reported that CR participation ranging from 3 to 6 months can improve physical fitness in 
patients [14]. However, patients in a CR program typically attend roughly 3 CR sessions 
per week and are generally exercising at a moderate intensity level. To our knowledge, 
this is the first study of its kind to observe resting hemodynamic variables in CR patients. 
Given that resting variables did not change in either group, it is possible that current CR 
exercise programs do not provide a large enough volume or a high enough intensity of 
aerobic activity to elicit significant changes in patients. This finding has practical 
significance in that the length of stay in a CR program may not be long enough for 
patients to attain cardiovascular benefits.  
There are a few limitations to the present study. First, the sample size was 
relatively small.  A larger subject sample would better allow us to analyze findings 
relative to each CVD diagnosis (MI, coronary artery bypass surgery, etc.). Second, no 
control was made for any medications that subjects were taking. Given that subjects 
recently underwent a significant CVD event (as evidenced by their referral to CR), it is 
likely that all subjects were taking at least one prescribed medication, which may have an 
impact on hemodynamic measures.  However, the nature of this study allowed for an 
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accurate representation of the standard CR patient, given that patients are not typically 
taken off their medications once admitted to a CR program. 
The findings of the present study do have clinically relevant importance. Previous 
data suggests that 43% of patients entering a CR program may be undiagnosed and 
untreated for OSA [13]. The present study had a sample of 73.3% subjects having 
evidence for OSA, suggesting that prevalence of undiagnosed OSA in a CR population 
may be higher than previously estimated. Furthermore, the subjects with untreated OSA 
appear to have a decrease in cardiac performance, manifesting through the decrease in 
CTi, the decrease in CI, the decrease in EF, and the increase in SVRi. This may indicate 
disease specific cardiovascular alterations. Epidemiological evidence suggests a causal 
relationship between the presence of OSA and CVD development [53], with severity of 
OSA having a strong association with CVD risk and all cause mortality [12, 54–57]. With 
the goals of CR programs being to reduce the risk of a secondary fatal MI and overall 
mortality [14, 15], these findings stress the importance of screening, diagnosing and 
treating OSA in a CR setting. 
In conclusion, this study did not reveal a significant change in resting 
hemodynamic variables from the beginning to the end of CR, regardless of the presence 
of OSA. Subjects with untreated OSA, however, did have depressed CI, CTi, and EF and 
an increased SVRi at both time points when compared to subjects without OSA. This 
would suggest that patients with untreated OSA have a decrease in cardiac function that 
may be a result of chronic exposure to vascular and hemodynamic fluctuations that occur 
during apneic events. 
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Table 1- Patient Characteristics 
 
OSA (n=33) Baseline Follow-Up 
AHI 17.2 ± 12.3 ---- 
Age (years) 65.0 ± 12.4 65.0 ± 12.4 
BMI (kg/m2) 31.4 ± 6.9 31.1 ± 6.8* 
Heart Rate (bpm) 64.1 ± 11.9 59.4 ± 8.0 
Systolic Arterial Pressure (mmHg) 121.3 ± 14.4 121.0 ± 14.3 
Diastolic Arterial Pressure (mmHg) 75.1 ± 10.7 71.9 ± 8.7 
6 Minute Walk Test (feet) § 1491.6 ± 267.6 1742.4 ± 254.3* 
 
Non-OSA (n=12) Baseline Follow-Up 
AHI 1.8 ± 1.3 ---- 
Age (years) 63.7 ± 11.2 63.7 ± 11.2 
BMI (kg/m2) 28.7 ± 4.1 28.3 ± 4.0* 
Heart Rate (bpm) 65.5 ± 12.3 64.3 ± 8.5 
Systolic Arterial Pressure (mmHg) 126.6 ± 24.4 130.2 ± 17.2 
Diastolic Arterial Pressure (mmHg) 72.0 ± 10.2 69.3 ± 7.7 
6 Minute Walk Test (feet) 1223.4 ± 357.0 1436.3 ± 404.9* 
 
Data are presented as mean ± SD.  
*Significant (p < 0.05) main effect for time. 
§ Significant (p<0.05) main effect for group.  
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Table 2- PhysioFlow Measurements  
 
OSA  Baseline Follow-Up 
Stroke Volume (mL/beat) 70.0 ± 29.0 79.0 ± 28.3 
Cardiac Output (L/min) 4.4 ± 1.7 4.7 ± 1.8 
Cardiac Index (L/min/m2) § 2.1 ± 0.7 2.2 ± 0.7  
Ejection Fraction (%) § 57.2 ± 11.2 59.6 ± 11.7  
LV Ejection Time (msec) 290.1 ± 76.2 310.0 ± 63.6 
Contractility Index § 105.2 ± 44.0 127.8 ± 53.3  
End Diastolic Volume (mL) 120.1 ± 31.8 134.8 ± 54.9 
Systemic Vascular Resistance (dyn·s/cm5) 1772.5 ± 863.4 1594.9 ± 623.7 
Systemic Vascular Resistance Index § 
(dyn·s/cm5) 
3730.2 ± 1852.4 3357.2 ± 1417.1  
 
Non-OSA Baseline Follow-Up 
Stroke Volume (mL/beat) 78.1 ± 14.3 78.7 ± 14.3 
Cardiac Output (L/min) 5.0 ± 1.0 5.0 ± 0.8 
Cardiac Index (L/min/m2) 2.6 ± 0.7 2.6 ± 0.4 
Ejection Fraction (%) 65.4 ± 9.5 65.4 ± 10.4 
LV Ejection Time (msec) 280.2 ± 87.3 280.3 ± 44.6 
Contractility Index 162.1 ± 55.7 160.7 ± 75.5 
End Diastolic Volume (mL) 121.4 ± 32.0 122.5 ± 25.8  
Systemic Vascular Resistance (dyn·s/cm5) 1373.4 ± 255.7 1351.2 ± 202.5 
Systemic Vascular Resistance Index 
(dyn·s/cm5) 
2690.2 ± 381.7 2660.8 ± 507.4 
 
Data are presented as mean ± SD.  
§ Significant (p<0.05) main effect for group.
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James Madison University/Rockingham Memorial Hospital 
Department of Kinesiology/Cardiac Rehabilitation Department 
Informed Consent 
 
Purpose 
 
You are being asked to take part in a research study conducted by Dr. Trent Hargens 
from James Madison University entitled, “The impact of obstructive sleep apnea on 
cardiac rehabilitation participation” because you are admitted in the Cardiac 
Rehabilitation Program at Rockingham Memorial Hospital.   
 
The primary goal of this study is to examine whether the presence of obstructive sleep 
apnea may impact the benefits of participating in Cardiac Rehabilitation.   
 
Experimental Procedures 
 
At Rockingham Memorial Hospital 
 
Once admitted into the Carilion Cardiac Rehabilitation Program, you will be asked to 
participate in this study during your orientation visit.  After the Informed Consent is 
signed, investigators will ask you to complete 2 one-page questionnaires to determine 
your risk of sleep apnea. In addition, a cardiac test will be offered to you. For this, you 
will be asked to lie down and relax, as 5 ECG electrodes will be placed on you to monitor 
the heart function.  This is non-invasive and does not cause any harm.  
 
You will also be asked to complete a six-minute walk test around the indoor track of the 
Cardiac Rehabilitation facility.  This is a standard test done in this setting, and you will 
be asked to walk as far as you can in six minutes.  Your heart rate and rhythm will be 
monitored throughout the test.  This test will not be any harder than any of the exercise 
you will do during Cardiac Rehabilitation.   
 
To better screen for sleep apnea, every patient will be provided with an at-home sleep-
testing device.  One of the researchers will teach you about setting up and using the small 
picket-sized recorder (the ApneaLink).  It is equipped with straps, a finger probe, and a 
nasal cannula.  You will be asked to wear this device for one entire night at home while 
you sleep.  It measures your breathing activity, heart rate, and blood oxygen levels.  The 
ApneaLink is a harmless monitor sometimes used by sleep doctors to screen people who 
may need more medical tests for possible nighttime breathing disorders.  The researcher 
will make plans for you to take the device home, assist you by phone if needed to 
properly set it up, and make plans for you to return it the next time you come to Cardiac 
Rehabilitation.   
 
The same night you wear the ApneaLink device, you will also be asked to wear a device 
called an accelerometer.  This device will be worn around the wrist, on the arm that you 
do not write with.  It is about the size of a large wristwatch.  It is harmless and is used to 
measure your movement while you sleep.  You will need to record the time you go to bed, 
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as well as the time you get out of bed.  There will be no setup of this device, other than to 
make sure it is on your wrist before you go to bed.   
 
The total time commitment for the tests described here will be about 25 minutes, in 
addition to the normal Cardiac Rehabilitation orientation activity. 
 
You will then begin your participation in Cardiac Rehabilitation.  Upon completion of the 
program, you will be asked to repeat the cardiac test and six-minute walk on your last day 
of Cardiac Rehabilitation. 
 
 
At James Madison University 
 
In addition to the test being done at Rockingham Memorial Hospital, you will be asked if 
you are willing to undergo one additional test, to be done at the Human Performance 
Laboratory, on the campus of James Madison University, in Godwin Hall room 209.  
This is an optional part of the study, and if you do not agree to this portion of the study, 
you will not be excluded from the rest of the study or from participating in Cardiac 
Rehabilitation.   
 
If you agree to this portion of the study, you will be asked to lie down in a quiet, 
darkened room for 10 minutes, after which an ultrasound probe (with gel) will be placed 
on your leg and arm to get images of your blood vessels.  After this, a blood pressure cuff 
will be placed on your arm and inflated for a period of 5 minutes.  After 5 minutes, the 
blood pressure cuff will be released we will again collect ultrasound images of the blood 
vessel in your arm.  We will collect images for 2 minutes after we release the blood 
pressure cuff.  We will then repeat this procedure for your leg.  If at any point during the 
5 minutes that the blood pressure cuff is on your leg or arm that you feel you need to stop 
the test, the researcher will immediately deflate the cuff.  This portion of the study will 
require about 30 – 45 minutes of your time. 
 
Once you are done with Cardiac Rehabilitation, you will be asked to return again to 
James Madison University and complete this test again, if you did these tests at the 
beginning. 
 
Risks 
 
There are no more than minimal risks associated with the questionnaire, wearing the 
ApneaLink device, or wearing an accelerometer.  However, there is some risk associated 
with the ultrasound measurements and six-minute walk test. 
 
The risks of the ultrasound blood pressure cuff procedure include discomfort often 
described as your arm is “falling asleep”; there is a temporary reduction or loss of feeling 
because the blood flow through the vessel is stopped for five minutes.  There is no long-
term risk associated with this procedure.  If, during the test, you feel that you cannot 
tolerate the discomfort, it will be immediately stopped.  In the unlikely event of cardiac 
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or other complications during the ultrasound test, an emergency plan is in place.  This 
includes immediate access to a phone to call emergency personnel.  In addition, each of 
the investigators is CPR certified.  You will not be doing anything strenuous during this 
test.  You will be at rest and lying down throughout the test. 
 
There is a risk of abnormal responses during the six-minute walk test.  These changes 
may include abnormal blood pressure, fainting, heart rhythm disorders, stroke, heart 
attack, and death.  The chance of serious heart problems during maximal exercise among 
adults is very small (less than 1/10,000 maximal exercise tests).  You will be 
continuously monitored by researchers and Cardiac Rehabilitation staff throughout the 
test.  The Cardiac Rehabilitation program has written emergency procedures to address 
exercise-related complications during this test, as well as during your participation in 
Cardiac Rehabilitation.   
 
Benefits 
 
There is no guarantee that you will get any benefit from taking part in this study.  
Benefits may include knowledge about your health status.  The questionnaires and at-
home sleep test will provide you with information concerning your risk for possible sleep 
apnea. Copies of the cardiac and sleep tests will be provided to you and you can decide to 
share these with your doctor. You will be referred to an appropriate health care 
professional, if necessary, based on your individual results. All costs related to follow-up 
appointments with these doctors, including further sleep evaluation, will be your 
responsibility and not the responsibility of James Madison University or Rockingham 
Memorial Hospital.  Indirect benefits of participating in this study will be helping the 
researchers to better understand how having sleep apnea may influence the benefits seen 
while participating in Cardiac Rehabilitation.    
 
 
Inquiries 
 
If you have any questions or concerns or you would like to receive a copy of the final 
aggregate results of this study, please contact Dr. Trent Hargens at hargenta@jmu.edu or 
(540) 568-5844. In the case of any immediate concerns or adverse reactions during the 
study, contact Dr. Hargens on his cell phone (540) 810-1310. 
 
Questions about Your Rights as a Research Subject 
Dr. David Cockley 
Chair, Institutional Review Board 
James Madison University 
(540) 568-2834 
cocklede@jmu.edu 
 
Confidentiality 
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All data and results will be kept confidential. You will be assigned an identification code. 
At no time will your name be identified with your individual data. The researcher retains 
the right to use and publish non-identifiable data. All data will be kept secured in a 
locked cabinet and password protected computer. Final aggregate results will be made 
available to participants upon request. 
 
Freedom of Consent 
 
Your participation is entirely voluntary.  You are free to choose not to participate.  
Should you choose to participate, you can withdraw at any time without consequences of 
any kind. 
 
 
I have read this consent form and I understand what is being requested of me as a 
participant in this study.  I freely consent to participate.  I have been given satisfactory 
answers to my questions.  The investigator provided me with a copy of this form.  I 
certify that I am at least 18 years of age. 
 
 
 
 
 
________________________________ __________________________________ 
Name of Subject (Printed)  Name of Researcher (Printed) 
 
________________________________ __________________________________ 
Name of Subject (Signed)  Name of Researcher (Signed) 
 
________________________________ __________________________________ 
Date     Date 
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Epworth Sleepiness Scale 
 
 
Subject ID______ Name______________________________ Date Completed ____/____/____ 
 
 
This questionnaire asks you to indicate the chances of you becoming drowsy during 
hours of the day that you are not in bed sleeping.  “How likely are you to doze off or fall 
asleep in the following situations?” 
 
Use the following scale and indicate the most appropriate number for each situation. 
 
    0 = would never doze 
    1 = slight chance of dozing 
    2 = moderate chance of dozing 
    3 = high chance of dozing 
 
 
 Situation       Chance of Dozing 
 
1. Sitting and reading       _____ 
 
2. Watching T.V.       _____ 
 
3. Sitting, inactive in a public place 
 (ex.  Theatre or meeting)      _____ 
 
4. As a passenger in a car for 
 an hour without a break      _____ 
 
5. Lying down to rest in the afternoon 
 when circumstances permit      _____ 
 
6. Sitting and talking with someone     _____ 
 
7. Sitting quietly after a lunch without alcohol    _____ 
 
8. In a car, while stopped for a few minutes 
 in the traffic        _____ 
 
 
 
 
Sum of Scores, items 1-8 (staff use only)    _____/24 
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Data Collection Sheet 
 
 
Patient Code_______     Date _____________     
 
Age __________ 
 
Height______ in/ ______cm     Weight ______lb/ ______kg    BMI_________kg/m^2 
 
 
6 minutes walk test ____________ 
 
Abdominal circumference __________  
 
Berlin Score___________ 
 
Epworth Score _________ 
 
Blood Pressure________________   
 
 
 
Calculations (Resting Values) 
 
Heart Rate (bpm) ___________________________ 
 
Stroke Volume (ml) _________________________ 
 
Cardiac Index (l/min/m^2) ___________________ 
 
Systemic vascular resistance __________________ 
 
Myocardial contractility ________________ 
 
 
Notes: 
________________________________________________________________________
________________________________________________________________________ 
 
 
Signature: _____________________ 
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